Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Launches Rosetta Resolver Version 2.0

NEW YORK, March 6 – Rosetta Inpharmatics has released Version 2.0 of its Rosetta Resolver gene expression data analysis system, the company announced Tuesday.

The chief improvement this update offers over Version 1.6, the last update released in October, is an improved ability to analyze data from single-color intensity-based DNA chips, the company said. 

"The majority of gene expression research is currently done on single-color DNA chips," Mary Drummond, senior director of marketing and sales at Rosetta, said in a statement. "Version 2.0 of the Rosetta Resolver system offers accelerated performance coupled with advanced analysis capabilities for single-color, intensity-based chips, as well as two-color, ratio-based chips ."

Version 2.0’s other added features include the ability to automatically process Affymetrix GeneChip array data files, and the capability to import, convert, and export data in Rosetta’s Gene Expression Markup Language format. The new version has automated sequence annotation updates from both public and proprietary databases, and can summarize and analyze data at the level of features, oligonucleotides, cDNA, probed pairs, sequences, exons, or cluster data. 

The new version also includes error models; and allows users to normalize data from single-color DNA chips, and perform pattern matching and cluster analysis algorithms on this data. The update’s error models produce P-values for each present/absent call and compute quality statistics for each intensity measurement. 

Rosetta is making Version 2.0 available through Agilent, its distribution partner.

The company did not disclose pricing information on the software, but said it is available in a number of different packages depending on the needs of the research organization.

Rosetta has so far licensed the Resolver system to GlaxoSmithKline, the Harvard Center for Genomic Research, Immunex, and Paradigm Genetics. Rosetta has also penned deals to use the technology in collaboration with Abbott Labs, Gemini Genomics, Monsanto, and Sangamo Biosciences.  

The company made its GEML markup language available for free in October, and has since formed a GEML consortium to promote free exchange of ideas and development of this software, with Agilent Technologies, Europroteome, GeneticXchange, the Harvard University Center for Genomic Research, InforMax, NetGenics, Nature Publishing Group, and Spotfire as its initial members.


The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.